Graniforce-MD Tablet contains Granisetron 1mg, a selective 5-HT3 receptor antagonist used primarily for the prevention of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery. Granisetron acts by blocking serotonin receptors located centrally in the chemoreceptor trigger zone and peripherally in the gastrointestinal tract, thereby inhibiting the emetic signaling pathways. This medication is indicated for patients undergoing highly emetogenic cancer treatments to improve quality of life by reducing the incidence and severity of nausea and vomiting. Graniforce-MD is administered orally, with dosing tailored according to the emetogenic potential of the treatment regimen and patient-specific factors. It is well tolerated with a favorable safety profile; common adverse effects may include headache, constipation, and transient elevations in liver enzymes. Caution is advised in patients with hepatic impairment, and dose adjustments may be necessary. Granisetron does not exhibit significant anticholinergic or extrapyramidal side effects, making it preferable in certain patient populations. Graniforce-MD should be used under medical supervision, with consideration of potential drug interactions, particularly with other serotonergic agents. Overall, Graniforce-MD Tablet is an effective antiemetic agent enhancing patient compliance and comfort during cancer therapy.